27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
- Biogen Inc (NASDAQ: BIIB) and Ginkgo Bioworks have entered into a gene therapy collaboration to develop a next-generation adeno-associated virus (AAV)-based vectors production platform.
- Under the terms of the agreement, Ginkgo will utilize its cell programming platform and capabilities to enhance the AAV production titers of Biogen's gene therapy manufacturing processes.
- Ginkgo will receive an upfront payment of $5 million and is eligible for milestone payments up to an additional $115 million.
- Earlier this month, Ginkgo Bioworks announced a SPAC deal with Soaring Eagle Acquisition Corp (NASDAQ: SRNG) that values the company at a pre-money equity value of $15 billion.
- Price Action: BIIB shares closed at $286.6 on Thursday.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!